



National Institute for Health and Clinical Excellence

Health Technology Appraisal

Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer

Royal College of Nursing

Introduction

The Royal College of Nursing was invited to comment on the Appraisal Consultation Document (ACD) of the technology appraisal of Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer. Nurses caring for lung cancer patients reviewed this document on behalf of the RCN.

The RCN welcomes the opportunity to comment on this document and responds below to the four questions on which comments were requested:

Appraisal Consultation Document – RCN Response

The Royal College of Nursing welcomes the opportunity to review the Appraisal Consultation Document (ACD) of the technology appraisal of Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer. The RCN's response to the four questions on which comments were requested is set out below:

i) **Has the relevant evidence been taken into account?**

This seems comprehensive and we are not aware of any new information that should be considered.

- ii) **Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence, and are the preliminary views on the resource impact and implications for the NHS appropriate?**

The summaries seem reasonable interpretations of the evidence. The preliminary views on the resource impact and implications for the NHS seem appropriate.

- iii) **Are the provisional recommendations of the Appraisal Committee sound and do they constitute a suitable basis for the preparation of guidance to the NHS?**

The provisional recommendations of the Appraisal Committee seem a suitable basis for preparation of guidance to the NHS.

- iv) **Are there any equality related issues that need special consideration that are not covered in the ACD?**

There do not appear to be any equality issues that have been missed otherwise at this stage.